The article talks about some people called 'insiders' who work for companies and buy more shares of the company's stock. When insiders buy more shares, it usually means they think the company is going to do well and make more money. This can be a good sign for people who want to buy the company's stock too. The article gives examples of three companies where insiders have been buying more shares: Adverum Biotechnologies, Appian, and American Strategic Investment. Read from source...

Avi Kapoor and Benzinga Staff Writer's article `More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying` seems to offer a balanced and objective insight into recent insider trades. However, a closer look reveals some inconsistencies and irrational arguments. The authors state that insider purchases can lend conviction to a buying decision but fail to mention the risks and potential downsides of following such trades blindly. Furthermore, the choice of stocks highlighted in this article appears to be somewhat arbitrary and not based on any robust analytical framework. Overall, the article seems to lack depth and objective analysis.

bullish

There are a few notable insider trades, and it's often seen as a positive sign when insiders purchase shares, indicating their confidence in the company's prospects or viewing the stock as a bargain. The article mentions three stocks where insiders have been making such purchases: Adverum Biotechnologies, Appian, and American Strategic Investment. These insider purchases, though not the only indicator for making an investment or trading decision, can lend conviction to a buying decision.

1. Adverum Biotechnologies (ADVM): Buy; Insider: Braden Michael Leonard; Purchase Details: 216,264 shares at an average price of $8.26; Cost: Around $1.79 million; Recent News: Data from ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD) released on July 17.

Risks:
- Clinical-stage gene therapy companies involve significant risks and uncertainties.
- Adverum Biotechnologies' financials may not support the value of the stock, especially if clinical trials fail to deliver positive results.
- The stock is highly volatile, which makes investing in it risky.

2. Appian Corporation (APPN): Buy; Insider: Colin T. Moran; Purchase Details: 300,000 shares at an average price of $35.40; Cost: Around $10.6 million; Recent News: Appian will release financial results for the second quarter, before the opening bell on Thursday, Aug. 1.

Risks:
- Appian is a low-code enterprise platform-as-a-service company focusing on business process management, which is a crowded space.
- Its financials may not support the value of the stock, especially if the company fails to deliver solid growth numbers in the upcoming results.
- There are significant competitive and regulatory risks in this industry.

3. American Strategic Investment Co. (NYC): Buy; Insider: New York City Advisors, LLC; Purchase Details: 125,864 shares at an average price of $10.98; Cost: Around $1.38 million; Recent News: On May 10, the company posted downbeat quarterly sales.

Risks:
- American Strategic Investment owns a portfolio of commercial real estate located within the five boroughs of New York City, which exposes it to significant market risks.
- The company's financials may not support the value of the stock, especially if the real estate market conditions worsen.
- The company's portfolio composition may limit diversification and increase concentration risk.

### Note:
These are just recommendations and involve significant risks and uncertainties. Investors should conduct their own research and due diligence before making any investment decision. Additionally, these recommendations are not financial advice and should not be construed as such.